Monopar Therapeutics Inc.
NASDAQMNPR heads into tomorrow's August 14 print with analyst conviction building and a short position that has shed nearly 40% of its mass in a month — yet enough residual bears remain to make this a genuine binary event. The analyst backdrop has turned more constructive than at any point this year. BTIG raised its price target to $133 yesterday — the day before earnings — maintaining…
MNPR short interest plunged 20.5% over the past week to 14.5% of float, marking the steepest decline in two months as availability surged to 114% — well above the 52-week average of 72%.
Snapshot as of 26 Sept 2026
MNPR heads into tomorrow's August 14 print with analyst conviction building and a short position that has shed nearly 40% of its mass in a month — yet enough residual bears remain to make this a genuine binary…
MNPR enters its August 14 earnings release with one of the more interesting short-covering stories in small-cap biotech right now — a high-conviction short position dissolving rapidly as the NDA clock ticks louder. The…
Monopar Therapeutics heads into its August earnings window with a stock that has more than doubled off its lows, shorts quietly trimming exposure, and the Street nudging targets higher — yet the borrow market remains…
Monopar Therapeutics has surged 30% in a single week — yet short interest remains near 24% of float and the lending pool is close to fully squeezed, making the tension between bulls and bears unusually charged. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MNPR — free to start on ORTEX.
Sign up for free →Open MNPR on ORTEX